Cancer/ ESMO2016/ R&D Cancer market commentary: 3 highlights from ESMO (Part 1) Andrew McConaghie AstraZeneca, breast, cancer, ESMO, Faslodex, kantar, Lynparza, Oncology, ovarian, pharma, treatment 0 Comment Commentary on key cancer data from ESMO by Stephanie Hawthorne Share X Cancer market commentary: 3 highlights from ESMO (Part 1) https://pharmaphorum.com/esmo-2016/cancer-market-commentary-3-highlights-esmo-conference-part-1/
Cancer/ ESMO2016/ R&D/ Views and analysis Eye on ESMO: Day 2 – gamechangers take centre stage Andrew McConaghie breakthrough, clinical trial, ESMO, Lilly, Oncology, ovarian, pharma, trial 0 Comment Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise Share X Eye on ESMO: Day 2 – gamechangers take centre stage https://pharmaphorum.com/esmo-2016/eye-esmo-day-two-gamechangers-take-centre-stage/
News/ R&D Clovis files key ovarian cancer drug in US Richard Staines AstraZeneca, cancer, Clovis, ovarian 0 Comment Rucaparib is only drug left in biotech’s pipeline. Share X Clovis files key ovarian cancer drug in US https://pharmaphorum.com/news/clovis-files-key-ovarian-cancer-drug-us/